[Angiogenesis Related Publications for VBF Steering
Committee]{.smallcaps}

## Kevin Camphausen

> Ergun, A., **Camphausen, K.,** Wein, L.: Optimal Scheduling of
> Radiotherapy and Angiogenic Inhibitors: A mathematical approach to the
> antiangiogenic hypothesis. Bulletin of Mathematical Biology 65:
> 407-424, 2003.
>
> Camphausen, K., Sproull, M., Tantama, S., Sankineni, S., Scott, T.,
> Menard, C., Coleman, N., Brechbiel, M.: Evaluation of copper chelation
> agents as anti-angiogenic therapy. Bioorganic and Medicinal Chemistry
> 11(19): 4287-93, 2003.
>
> Chan, L., Moses, M., Goley, E., Sproull, M., Muanza, T., Coleman, N.,
> Figg, W., Menard, C., Camphausen, K.: Predictive significance of
> urinary vascular endothelial growth factor (VEGF) and matrix
> metalloproteinase (MMP) levels and trends in patients with cancer.
> Journal of Clinical Oncology 22(3): 499-506, 2004.
>
> Beecken, W.-D., Engl, T., Blaheta, R., Bentas, W., Achiles, E.-G.,
> Shing, Y., Camphausen, K., Effect of angiogenesis inhibitors on
> cyclophosphamide induced bladder inflammation in mice. Angiogenesis
> 7(1): 69-73, 2004.
>
> Citrin, D., Lee, A., Scott, T., Sproull, M., Menard, C., Tofilon, P.,
> Camphausen, K.: *In vivo* tumor imaging in mice with near infrared
> labeled Endostatin. Molecular Cancer Therapeutics 3(4): 481-488, 2004.

# 

# Ménard, C., Susil, R., Choyke, P., Coleman, J., Grubb, R., Gharib, A., Krieger, A., Guion, P., Thomasson, D., Ullman, K., Goley, E., Espina, V., Liotta, L., Petricoin, E., Merino, M., Whitcomb, L., Atalar, E., Coleman, N., Camphausen, K.: **Molecular processes that underlie heterogeneity in perfusion magnetic resonance images (MRI) of the prostate gland can be determined with interventional MRI. In press**

> Camphausen, K., Sproull, M., Tantama, S., Venditto, V., Sankineni, S.,
> Scott, T., Brechbiel, M.: Evaluation of chelating agents as
> anti-angiogenic therapy through copper chelation. Bioorganic Medicinal
> Chemistry 12(19): 5133-40, 2004.
>
> Susil, R., Camphausen, K., Choyke, P., McVeigh, E., Gustafson, G.,
> Ning, H., Miller, R., Atalar, E., Colman, N., Menard, C.: System for
> prostate brachytherapy and biopsy in a standard 1.5T MRI scanner.
> Magnetic Resonance Medicine 52(3): 683-7, 2004.
>
> Camphausen, K., Don, A., Creighton, B., Donoghue, N., Beckner, C.,
> Joussen, A., Folkman, J., O'Reilly, M., Hogg, P.: Imaging of apoptosis
> using a hydrophilic trivalent arsinical. Submitted.
>
> Beecken, W.D., Camphausen, K., Fernandez, A., Achilles, E.G., Kilroy,
> S., Moses, M., Shing, Y.: Angiostatin expression in human bladder
> cancer. Submitted
>
> Ménard, C., Susil, R.C., Choyke, P., Gustafson, G., Kammerer, W.,
> Ning, H., Miller, R.W., Ullman, K., Sears Crouse, N., Smith, S.,
> Lessard, E., Pouliot, J., Wright, V., McVeigh, E., Coleman, C. N.,
> Camphausen, K.: MRI-Guided HDR Prostate Brachytherapy in a Standard
> 1.5T Scanner. International journal of radiation oncology biology and
> physics 59(5): 1414-23, 2004.
>
> Boyer, D., Oldfield, E., Heiss, J., Coleman, N., Fuller, B.,
> Camphausen, K.: Radiosurgery for cerebellar hemangioblastomas
> associated with von Hippel-Lindau syndrome: Experience at the National
> Cancer Institute. *Submitted*
>
> Beecken, W., Engl, T., Engels, K., Blumenberg, C., Oppermann, E.,
> Camphausen, K., Shing, Y., Jonas, D., Blaheta, R.: Clinical relevance
> of maspin expression in bladder cancer. Submitted.
>
> Citrin, D., Ning, H., Guion, P., Li, G., Susil, R.C., Miller, R.W.,
> Lessard, E., Pouliot, J., Xie, H., Capala, J., Coleman, N.C.,
> Camphausen, K., Ménard, C. Inverse Treatment Planning Based on MRI for
> HDR Prostate Brachytherapy. International Journal of Radiation
> Oncology Biology and Physics 61(4): 1267-75, 2005.
>
> Li, G., Xie, H., Ning, H., Capala, J., Arora, B., Coleman, N.,
> **Camphausen, K.**, Miller, R.: Volumetric voxel image registration:
> development for multi-modality image fusion. Submitted
>
> Amyot, F., **Camphausen, K.,** Siavosh, A., Gandjbakche, A.:
> Quantitative method to study the network formation of endothelial
> cells in response to tumor angiogenic factor. Submitted.
>
> Beecken, W-D., Engl, T., **Camphausen, K.,** Michaelis, M., Jonas, D.,
> Folkman, J., Shing, Y., Blaheta, R.: An endogenous inhibitor of
> endothelial cell growth from transitional cell carcinoma: clipped
> β~2~-glycoprotein-I. *Submitted*
>
> Folkman, J., **Camphausen, K**.: What does radiotherapy do to the
> endothelial cells? Science 293: 114-116. 2001.
>
> Coleman, N., **Camphausen, K.,** Mitchell, J.: Tumor hypoxia: chicken,
> egg or a piece of the farm?. Journal of Clinical Oncology, Feb 1:
> 20(3): 610-615, 2002.
>
> **Camphausen, K.,** Menard, C.: Angiogenesis inhibitors and
> radiotherapy of primary tumors. Expert Opinion on Biological Therapy.
> 2(5); 477-481, June 2002.
>
> **Camphausen, K.:** A portrait of an editorial board member: Judah
> Folkman. Cell Cycle. 1(5); 296-297, 2002.
>
> Sproull, M., Brechbiel M., **Camphausen, K.:** Anti-angiogenic therapy
> through copper chelation. Expert Opnion on Therapeutic Targets. 7(3):
> 405-9, 2003.
>
> Citrin, D., Scott, T., Sproull, M., Menard, C., Tofilon, P.,
> **Camphausen, K.**: In vivo tumor imaging utilizing a near-infrared
> labeled Endostatin molecule. International Journal of Radiation
> Oncology Biology and Physics 58(2): 536-541, 2004.
>
> Chan, L., **Camphausen, K.:** Angiogenic tumor markers,
> anti-angiogenic agents and radiation therapy. Expert Review of
> Anti-cancer therapy 3(3): 357-66, 2003.
>
> **Camphausen, K.:** Combination therapy with anti-angiogenic agents
> and radiotherapy. European Journal of Cancer, 13 (13 Suppl.), 2002.
>
> Citrin, D., **Camphausen, K.:** Murine in vivo imaging and its role in
> preclinical modeling of novel agents. Expert review of Anticancer
> Therapy, 4(5): 857-864, 2004.
>
> Citrin, D., Menard, C., **Camphausen, K.:** Combining radiotherapy and
> angiogenesis inhibitors: clinical trial design. In press
>
> **Camphausen, K.,** Menard, C. The combination of angiogenesis
> inhibitors and radiotherapy for the treatment of primary tumors. *In:*
> Pharmacokinetics and pharmacodymanics of anti-cancer drugs. Eds:
> William Figg and Howard McLeod. Humana Press Totowa, NJ. Pages
> 431-438, 2004.
>
> Anderson, S., Chan, L., **Camphausen, K.:** Vascular Endothelial
> Growth Factor effect upon angiogenesis and hypercoagulopathy in
> glioblastoma multiforme and other conditions. Check Sample. Clinical
> Chemistry 43: 2003.

## Frank Cuttitta

> Martínez A, Vos M, Guédez L, Kaur G, Chen Z, Garayoa M, Pío R, Moody
> T, Stetler-Stevenson WG, Kleinman HK, and **Cuttitta F**.  The effect
> of adrenomedullin overexpression in breast tumor cells.  J Natl Cancer
> Inst 94:1226-1237, 2002.
>
> Zudaire E, Martínez A, and **Cuttitta F**.  Adrenomedullin and cancer.
> Reg Peptides 112(1-3):175-183, 2003.
>
> Martínez A, Julián M, Bregonzio C, Notari L, Moody TW, and **Cuttitta
> F**.  Identification of vasoactive non-peptidic positive and negative
> modulators of adrenomedullin using a neutralizing antibody-based
> screening strategy.  Endocrinology, 145:3858-3865, 2004.
>
> Martínez A, Zudaire E, Portal-Núñez, Guédez L, Stetler-Stevenson WG,
> and **Cuttitta F**.  Proadrenomedullin N-terminal 20 peptide is a
> potent angiogenic factor and its inhibition results in reduction of
> tumor growth.  Cancer Res 64:6489-6494, 2004.
>
> Martínez A, Oh H-R, Unsworth EJ, Bregonzio C, Saavedra JM,
> Stetler-Stevenson WG, and **Cuttitta F. ** Matrix metalloproteinase-2
> cleavage of adrenomedullin produces a vasoconstrictor out of a
> vasodilator.  Biochem J 383:413-418, 2004.
>
> Martínez A, Zudaire E, Julián M, Moody WT, and **Cuttitta F**. 
> Gastrin-releasing peptide (GRP) induces angiogenesis and the specific
> GRP blocker 77427 inhibits tumor growth in vitro and in vivo. 
> Oncogene, March 7, 2005 \[Epub ahead of print\], PMID: 15750618.
>
> Zudaire E, Martínez A, Garayoa M, Pío R, Kaur G, Woolhiser MR,
> Metcalfe DD, Hood WA, Siraganian RP, Guise TA, Chirqwin JM, and
> **Cuttitta F**.  Adrenomedullin is a cross-talk molecule that
> regulates tumor and mast cell function during human carcinogenesis. 
> Am J Pathol,  (In Press) 

## Steve Libutti

> Calvo, A., Feldman, A. L., **Libutti, S. K.**, and Green, J. E.
> Adenovirus-mediated Endostatin Delivery Results in Inhibition of
> Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice.
> Cancer Res, 62:3934-3938, 2002.
>
> Calvo, A., Yokoyama, Y., Smith, L. E., Ali, I., Shih, S. C., Feldman,
> A. L., **Libutti, S. K.**, Sundaram, R., and Green, J. E. Inhibition
> of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic
> mice by a mutated form of human endostatin. Int J Cancer, 101:224-234,
> 2002.
>
> Choyke, P. L., Knopp, M. V., and **Libutti, S. K.** Special techniques
> for imaging blood flow to tumors. Cancer J, 8:109-118, 2002.
>
> Costouros, N. G., Diehn, F. E., and **Libutti, S. K.** Molecular
> imaging of tumor angiogenesis. J Cell Biochem Suppl, 39:72-78, 2002.
>
> Feldman, A. L., Alexander, H. R., Jr., Yang, J. C., Linehan, W. M.,
> Eyler, R. A., Miller, M. S., Steinberg, S. M., and **Libutti, S. K.**
> Prospective analysis of circulating endostatin levels in patients with
> renal cell carcinoma. Cancer, 95:1637-1643, 2002.
>
> Friedl, J., Puhlmann, M., Bartlett, D. L., **Libutti, S. K.**, Turner,
> E. N., Gnant, M. F., and Alexander, H. R. Induction of permeability
> across endothelial cell monolayers by tumor necrosis factor (TNF)
> occurs via a tissue factor-dependent mechanism: relationship between
> the procoagulant and permeability effects of TNF. Blood,
> 100:1334-1339, 2002.
>
> Lans, T. E., Ten Hagen, T. L., Van Horssen, R., Wu, P. C., Van Tiel,
> S. T., **Libutti, S. K.**, Alexander, H. R., and Eggermont, A. M.
> Improved Antitumor Response to Isolated Limb Perfusion With Tumor
> Necrosis Factor After Upregulation of Endothelial Monocyte-Activating
> Polypeptide II in Soft Tissue Sarcoma. Ann Surg Oncol, 9:812-819,
> 2002.
>
> Libutti, S. K. and Costouros, N. G. Microarray technology and gene
> expression analysis for the study of angiogenesis. Expert Opin Biol
> Ther, 2:545-556, 2002.
>
> Zogakis, T. G., Costouros, N. G., Kruger, E. A., Forbes, S., He, M.,
> Qian, M., Feldman, A. L., Figg, W. D., Alexander, H. R., Liu, E. T.,
> Kohn, E. C., and **Libutti, S. K.** Microarray gene expression
> profiling of angiogenesis inhibitors using the rat aortic ring assay.
> Biotechniques, 33:664-666, 668, 670, 2002.
>
> Keezer, S. M., Ivie, S. E., Krutzsch, H. C., Tandle, A., **Libutti, S.
> K.**, and Roberts, D. D. Angiogenesis Inhibitors Target the
> Endothelial Cell Cytoskeleton through Altered Regulation of Heat Shock
> Protein 27 and Cofilin. Cancer Res, 63:6405-6412, 2003.
>
> Kurdziel, K. A., Figg, W. D., Carrasquillo, J. A., Huebsch, S.,
> Whatley, M., Sellers, D., **Libutti, S. K.**, Pluda, J. M., Dahut, W.,
> Reed, E., and Bacharach, S. L. Using Positron Emission Tomography
> 2-Deoxy-2-\[18F\]Fluoro-D-Glucose, 11CO, and 15O-Water for Monitoring
> Androgen Independent Prostate Cancer. Mol Imaging Biol, 5:86-93, 2003.
>
> Oliver, V. K., Patton, A. M., Desai, S., Lorang, D., **Libutti, S.
> K.**, and Kohn, E. C. Regulation of the pro-angiogenic
> microenvironment by carboxyamido-triazole. J Cell Physiol,
> 197:139-148, 2003.
>
> Feldman, A. L., Stetler-Stevenson, W. G., Costouros, N. G., Knezevic,
> V., Baibakov, G., Alexander, H. R., Jr., Lorang, D., Hewitt, S. M.,
> Seo, D. W., Miller, M. S., O\'Connor, S., and **Libutti, S. K.**
> Modulation of tumor-host interactions, angiogenesis, and tumor growth
> by tissue inhibitor of metalloproteinase 2 via a novel mechanism.
> Cancer Res, 64:4481-4486, 2004.
>
> **Libutti, S. K.** Do angiogenesis inhibitors perform a physiologic
> gatekeeper role in cancer prevention? Cancer J, 10:12-14, 2004.
>
> Mazzanti, C. M., Tandle, A., Lorang, D., Costouros, N., Roberts, D.,
> Bevilacqua, G., and **Libutti, S. K.** Early genetic mechanisms
> underlying the inhibitory effects of endostatin and fumagillin on
> human endothelial cells. Genome Res, 14:1585-1593, 2004.
>
> McDonald, D. M., Teicher, B. A., Stetler-Stevenson, W., Ng, S. S.,
> Figg, W. D., Folkman, J., Hanahan, D., Auerbach, R., O\'Reilly, M.,
> Herbst, R., Cheresh, D., Gordon, M., Eggermont, A., and **Libutti, S.
> K.** Report from the Society for Biological Therapy and Vascular
> Biology Faculty of the NCI Workshop on Angiogenesis Monitoring. J
> Immunother, 27:161-175, 2004.
>
> Miller, W. J., Kayton, M. L., Patton, A., O\'Connor, S., He, M., Vu,
> H., Baibakov, G., Lorang, D., Knezevic, V., Kohn, E., Alexander, H.
> R., Stirling, D., Payvandi, F., Muller, G., and **Libutti, S. K.** A
> novel technique for quantifying changes in vascular density,
> endothelial cell proliferation and protein expression in response to
> modulators of angiogenesis using the chick chorioallantoic membrane
> (CAM) assayChorioallantoic Membrane (CAM) Assay. J Transl Med, 2:4,
> 2004.
>
> Tandle, Blazer, I. G., and **Libutti, S. K.** Antiangiogenic gene
> therapy of cancer: recent developments. J Transl Med, 2:22, 2004.

**[Dave Roberts]{.smallcaps}** - 2003 - To Date

> Keezer, S. M., Ivie, S. E., Krutzsch H. C., Tandle, A., Libutti, S.,
> and **Roberts, D. D.**: Angiogenesis inhibitors target the endothelial
> cell cytoskeleton through altered regulation of Hsp27 and cofilin.
> *Cancer Res.* 63:6405-6412, 2003.
>
> Calzada, M. J., Sipes, J. M., Krutzsch, H. C., Yurchenco, P. D.,
> Annis, D. S., Mosher, D. F., and **Roberts, D. D.**: Recognition of
> the N-terminal modules of thrombospondin-1 and thrombospondin-2 by
> a6b1 integrin. *J. Biol. Chem.* 278:40679-40687, 2003.
>
> Calzada, M. J.**,** Zhou, L, Sipes, J. M., Zhang, J., Krutzsch, H. C.,
> Iruela-Arispe, M. L., Annis, D. S., Mosher, D. F., and **Roberts, D.
> D.**: a4b1 Integrin mediates selective endothelial cell responses to
> thrombospondins *in vitro* and modulates angiogenesis *in vivo*.
> *Circ. Res.* 94: 462-470, 2004.
>
> Mazzanti, C. M., Tandle, A., Lorang, D., Costouros, N., **Roberts, D.
> D.**, Bevilacqua, G., and Libutti, S. K.: Early genetic mechanisms
> underlying the inhibitory effects of endostatin and fumagillin on
> human endothelial cells. *Genome Res.* 14:1585-1593, 2004.
>
> Calzada, M. J., Annis, D. S., Zeng, B., Marcinkiewicz, C., Banas, B.,
> Lawler, J., Mosher, D. F., and **Roberts, D. D.**: Identification of
> novel b1 integrin binding sites in the type 1 and type 2 repeats of
> thrombospondin-1. *J. Biol. Chem.* 279:41734-41743, 2004.
>
> Calzada, M. J. and **Roberts, D. D.**: Novel integrin antagonists
> derived from thrombospondins. *Curr. Pharm. Des.* 11 (7): 849-866,
> 2005.
>
> Isenberg, J. S., Espey, M., Ridnour, L., Wink, D., and **Roberts, D.
> D.**: Nitric oxide in wound healing. *Microsurgery* (in press).
>
> Tandle, A. T., Mazzanti, C., Alexander, H. R., **Roberts D. D.**, and
> Libutti, S. K.: EMAP-II induced gene expression changes in endothelial
> cells. *Cytokine* (in press)
>
> Isenberg, J. S., Calzada, M. J., Zhou, L., Guo, N., Lawler, J., Wang,
> X., Frazier, W. A., and **Roberts, D. D.**: Endogenous
> thrombospondin-1 is not necessary for proliferation but is permissive
> for vascular smooth muscle cell responses to platelet-derived growth
> factor. *Matrix Biol.* (In press)